Axitinib Palladium Catalyst Preparation for Faster Low-Residue Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing Axitinib are inefficient due to long reaction times and high palladium catalyst usage, which complicates purification and increases costs.
Innovation Solution
A process involving a palladium catalyst prepared separately as a mixture of a palladium source, ligand, and base, used in combination with 2-vinylpyridine to react with compound (III), followed by deprotection, reduces catalyst amount and reaction time, and includes purification steps to enhance yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the prior art process using Pd catalyst is used, then the reaction can proceed, but the reaction time is long (24 hours) and Pd catalyst amount is high
Solution Approach 1:
The patent changes the parameters of the palladium catalyst system by using a specifically prepared mixture containing Pd source, ligand, and base in controlled proportions. This parameter optimization enables the reaction to complete in significantly reduced time while maintaining high efficiency and reducing catalyst dosage.
Solution Approach 2:
The palladium catalyst is prepared separately in advance as a pre-mixed solution containing the Pd source, ligand, and base. This preliminary preparation of the catalyst system allows for optimized reaction conditions to be applied immediately, reducing the overall reaction time from 24 hours to a much shorter duration.
2Productivity
If high amount of Pd catalyst is used, then the reaction proceeds efficiently, but removal of Pd from final compound is not trivial and costs increase
Solution Approach 1:
By optimizing the catalyst composition parameters (Pd source, ligand, base ratios) and using a pre-prepared catalyst mixture, the reaction achieves high efficiency with reduced Pd loading. This parameter optimization simultaneously improves ease of manufacture by reducing the burden of Pd removal from the final product.
Solution Approach 2:
The patent employs a disposable pre-prepared catalyst solution that is optimized for single-use efficiency. This approach allows for minimal Pd residue in the final product, reducing the need for extensive purification steps and making the manufacturing process easier and more cost-effective.
3Productivity
If Pd catalyst is used, then the cross-coupling reaction occurs, but the amount of Pd residue in final product increases
Solution Approach 1:
The patent optimizes the catalyst system parameters by using a specifically formulated mixture of Pd source, ligand, and base. This parameter optimization maintains high reaction yield while minimizing Pd residue in the final product, thereby improving chemical purity without sacrificing productivity.
Solution Approach 2:
The ligand and base in the pre-prepared catalyst mixture act as intermediaries that facilitate the cross-coupling reaction while controlling Pd deposition. This intermediary system enables high yield reaction while keeping Pd residue levels low, improving the manufacturing precision of the final Axitinib product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a significant reduction in reaction time, lowers palladium residue to under 10 ppm, and improves chemical purity of Axitinib, making it suitable for industrial-scale production.
Implementation Method 1
reacting of compound of formula (III) with 2-vinylpyridine in a presence of a palladium catalyst wherein the palladium catalyst is a mixture comprising a palladium source, a ligand and a base
Implementation Method 2
Deprotecting compound of formula (IV) to provide compound of formula (I) or a salt thereof
Data Source
AI summary
In a process of making Axitinib, a palladium catalyst is added to a mixture of 2-vinylpyridine and the protected intermediate of formula (III) to form protected-Axitinib of formula (IV).In the formulas, P is a protective group and X is I, Cl, Br, or trifluoromethanesulfonate. The palladium catalyst is prepared separately, before being added to the reaction mixture, and is made from a mixture of a palladium source, a ligand, and a base in a suitable solvent. By adding the palladium catalyst to this protected intermediate, the process can use lower amounts of palladium and can have faster reaction times.